Stockreport

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

Mural Oncology plc - Ordinary Shares  (MURA) 
PDF Mural’s lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which ar [Read more]